Initial Management of Intrarenal (Intrinsic) Acute Kidney Injury
The cornerstone of managing intrarenal AKI is immediate discontinuation of all nephrotoxic medications, aggressive optimization of fluid status to achieve euvolemia, and identification of the specific intrinsic cause (acute tubular necrosis, glomerulonephritis, acute interstitial nephritis, or vascular injury) to guide targeted therapy 1, 2.
Immediate Actions Upon Recognition
1. Stop All Nephrotoxic Agents
- Discontinue NSAIDs, ACE inhibitors, ARBs, and diuretics immediately 3, 2
- Review all medications for nephrotoxic potential—each nephrotoxin increases AKI odds by 53%, and combining 3+ nephrotoxins doubles the risk 3
- Avoid the "triple whammy" combination (NSAIDs + diuretics + ACE inhibitors/ARBs) which causes pharmacodynamic interactions 3
- Adjust dosing of essential medications based on current renal function with pharmacist consultation 2
Critical caveat: If treating life-threatening infection, start necessary antibiotics immediately—delaying treatment worsens outcomes more than potential nephrotoxicity 3. Use therapeutic drug monitoring for aminoglycosides 4.
2. Optimize Volume Status
- Assess for euvolemia through clinical examination and daily fluid balance monitoring 2
- For volume depletion: administer isotonic crystalloids (normal saline or balanced solutions) 1, 4
- For volume overload: restrict fluids and consider diuretic therapy or renal replacement therapy 1
- Measure serum creatinine, urea, and electrolytes (sodium, potassium, bicarbonate) at least every 48 hours, more frequently if unstable 2
The 2020 KDIGO conference highlights ongoing controversy about whether 0.9% saline versus balanced solutions affects kidney outcomes—both are acceptable for initial resuscitation 1.
3. Identify the Specific Intrinsic Cause
Differentiate between the major intrinsic causes:
- Acute Tubular Necrosis (ATN): Most common intrinsic cause; look for recent hypotension, sepsis, nephrotoxin exposure, or contrast administration
- Acute Interstitial Nephritis: Consider with recent medication changes (antibiotics, PPIs, NSAIDs); look for fever, rash, eosinophilia
- Glomerulonephritis: Suspect with hematuria, proteinuria, systemic symptoms
- Vascular causes: Consider with embolic phenomena, recent procedures, or thrombotic risk factors
Diagnostic workup to perform immediately:
- Urinalysis with microscopy (look for muddy brown casts in ATN, RBC casts in glomerulonephritis, WBC casts in interstitial nephritis)
- Fractional excretion of sodium (FENa): >2% suggests intrinsic AKI 5, 6
- Urine sodium: >40 mEq/L indicates intrinsic disease 6
- Complete blood count with differential
- Renal ultrasound to exclude obstruction 5
4. Consider Kidney Biopsy for Specific Diagnoses
Urgent nephrology consultation and kidney biopsy are indicated when:
- Glomerulonephritis is suspected (requires immunosuppressive therapy)
- Acute interstitial nephritis is likely and causative drug cannot be identified
- Vasculitis is in the differential
- Diagnosis remains unclear after initial workup and management decisions depend on histology 1
The 2020 KDIGO conference emphasizes defining the role of kidney biopsy in AKI management as a research priority 1.
Supportive Management
Electrolyte and Acid-Base Management
- Monitor potassium closely; treat hyperkalemia aggressively (>6.0 mEq/L or with ECG changes)
- Address metabolic acidosis; consider sodium bicarbonate for severe acidosis (pH <7.2), though evidence is limited 1
- Correct hypocalcemia and hyperphosphatemia as needed
Indications for Renal Replacement Therapy
Initiate dialysis for:
- Refractory hyperkalemia (>6.5 mEq/L despite medical management)
- Volume overload unresponsive to diuretics with pulmonary edema
- Severe metabolic acidosis (pH <7.1) refractory to bicarbonate
- Uremic complications (encephalopathy, pericarditis, bleeding)
- Certain toxin ingestions 5, 7
Monitoring and Recovery Phase
- Continue nephrotoxin avoidance during the recovery phase—the kidney remains vulnerable to re-injury 3
- Monitor for progression to chronic kidney disease; even transient AKI increases CKD risk 3, 8
- Educate patients to avoid NSAIDs and consult before starting new medications 3
- Arrange nephrology follow-up within 3 months for all patients with Stage 2-3 AKI 2
Key Pitfalls to Avoid
Do not assume volume depletion without assessment—intrinsic AKI often coexists with euvolemia or volume overload; inappropriate fluid administration worsens outcomes 1, 2
Do not continue nephrotoxins "because the patient needs them"—reassess necessity daily and use less nephrotoxic alternatives when possible 3
Do not delay nephrology consultation for unclear cases—early specialist involvement improves outcomes, particularly when biopsy may change management 1
Do not use fenoldopam or theophylline for prevention or treatment—these are not recommended and may cause harm 4